Infectious Diseases

Respiratory Viral Panel
Comprehensive. Reliable. Fast.

A FDA Approved Clinically Proven Test for 22 Respiratory Viral and Bacterial Infections

  • Viral Targets

    • Influenza A, A H1, A H3, 2009 H1N1
    • Influenza B
    • Respiratory Syncytial Virus A &B (RSV )
    • Parainfluenza Virus 1, 2, 3, 4
    • Human Bocavirus, Human Metapneumovirus (hMPV), Human Rhinovirus/Enterovirus
    • Adenovirus
    • Coronavirus HKU1, NL63, OC43, 229E

  • Bacterial Targets

    • Chlamydophila pneumoniae
    • Mycoplasma pneumoniae
    • Bordetella pertussis


The GeneSYS Respiratory Viral Panel (RVP) simultaneously detects and identifies multiple respiratory virus DNA in nasopharyngeal swabs from individuals suspected of respiratory tract infections.


  • Advantages of Genesys RVP

    • Comprehensive: Tests for 22 different respiratory viruses and bacterial infections including Flu A subtypes (H1 and H3) in a single assay
      Capable of detecting and identifying multiple pathogens in a sample
    • Reliable: This assay exhibits excellent clinical sensitivity and specificity and high reproducibility
    • Fast: 24 hour turn-around-time (Fast enough to impact patient treatment decisions)
    • Rule Out Other Causes : Reduce Testing
    • Antibiotic Stewardship: Reduce rise of resistance
    • Reduce Spread: Cohorting inpatients
    • Improve health outcome and reduce cost : 15-60 million infected with flu/year in U.S., $40Billion economic burden in U.S.
    • Non - Flu viruses and respiratory viral co-infection: Disease severity can be high in patients with comorbidities


Respiratory viruses are responsible for a wide range of acute respiratory tract infections including the common cold, influenza and croup and represent the most common cause of acute illness in the U.S. Disease severity can be especially high in the young, the immunocompromised and elderly patients. Diagnosis of respiratory infection by clinical symptoms alone is extremely difficult and often inaccurate due to non-specific symptoms.


Integrated multiplex PCR and bead hybridization detection offers a highly sensitive and specific method of respiratory pathogen detection. In addition, another benefit is the ability to obtain the results in hours with the detection of co-infections. Evidence suggests patients with co-infections have an increased disease severity and more complex clinical management.


Results Interpretation:
The detection of 19 respiratory viral targets and 3 bacterial targets is simultaneous in each sample with an integrated multiplex PCR and bead hybridization platform. Our easy to read report available electronically, based upon the presence (Positive) or absence (Negative) of the viruses or bacteria within the panel will allow our clients to rapidly choose a treatment option. Co-infections occur approximately 20-30% of the time, therefore, there may be more than one virus detected and reported.

    Why consider offering a panel?


  • Panels help identify co-infection and more at risk patients.
    Co-infections occur 20%-30% of the time and more than one Virus is detected and reported. Detection of the 19 viral and 3 bacterial targets occurs simultaneously.

    On average 24,000 deaths each year are attributed to influenza in the U.S. In children, respiratory syncytial virus (RSV) is the most common cause of severe lower respiratory tract infection worldwide.

    Timely detection of these viruses can lead to initiation of proper antiviral treatment, decreased use of unnecessary antibiotics, reduced transmission of disease from person to person and better clinical outcomes.


    Test information

  • Description Respiratory Pathogen Panel
    Method Integrated multiplex PCR and bead hybridization
    CPT Code 87633, 87486, 87581, 87798
    ICD10 Codes J11.00: Influenza due to unidentified influenza
    J98.9: Respiratory Disorder, unspecified
    B34.9: Viral infection, unspecified
    A49.9: Bacterial infection of unspecified site
    J06.9: Acute upper respiratory infection, unspecified
    Specimen Requirements Flocked nasopharyngeal swab in viral transport media shipped at room temperature
    Turnaround Time 24 Hrs
    Shipping Pickup/Fedex Service Available Monday – Friday
    Testing Performed Monday-Saturday



  • How GeneSYS can help

    • Our extensive insurance network includes most major payers, so testing is typically covered for patients who meet current guidelines
    • Our online portal provides results instantaneously
    • Our LIS integration with EMRs simplifies results availability and frees up time for your clinic

Gastrointestinal (GI) Panel
Comprehensive. Reliable. Fast.

A FDA Approved Clinically Proven Test for 14-22 Bacterial, Parasitic, and Viral Infections

  • Basic Panel


    Bacterial Targets

    • Campylobacter
    • Clostridium difficile (toxin A/B)
    • E. coli O157
    • Enterotoxigenic E. coli (ETEC) It/st
    • Salmonella
    • Shiga-like toxin-producing E. coli (STEC) stx1/stx2
    • Shigella
    • Vibrio cholerae



    Parasites

    • Cryptosporidium
    • Entamoeba histolytica
    • Giardia



    Viruses

    • Adenovirus 40/41
    • Norovirus GI/GII
    • Rotavirus A

  • Expanded Panel

    • Enteroaggregative E. coli (EAEC)
    • Enteropathogenic E. coli (EPEC)
    • Plesiomonas shigelloides
    • Shigella/Enteroinvasive E. coli (EIEC)*
    • Vibrio (parahaemolyticus, vulnificus)
    • Yersinia enterocolitica
    • Cyclospora cayetanensis
    • Astrovirus
    • Sapovirus (I, II, IV, and V)


GDI’s Gastrointestinal Panel simultaneously tests for common gastrointestinal pathogens including viruses, bacteria and parasites that cause infectious diarrhea.


Integrated multiplex PCR and bead array technology detection offers a highly sensitive and specific method of gastrointestinal pathogen detection. In addition, another benefit is the ability to obtain the results in hours with the detection of co-infections.


  • Advantages of Genesys GIP

    • Comprehensive: Tests for 14-22 different bacterial, parasitic and viral targets in a single test
      Capable of detecting and identifying multiple pathogens in a sample
    • Reliable: This assay exhibits excellent clinical sensitivity and specificity and high reproducibility
    • Fast: 24 hour turn-around-time (Fast enough to impact patient treatment decisions)
    • Rule Out Other Causes : Reduce Testing
    • Antibiotic Stewardship: Reduce rise of resistance
    • Reduce Spread: Cohorting inpatients
    • Improve health outcome and reduce cost : In the United States, an estimated $6 billion each year is spent on medical care and lost productivity due to foodborne diseases, most of which cause diarrhea.


Results Interpretation:
The detection of 14-22 gastrointestinal targets are simultaneous in each sample with an integrated multiplex PCR and bead hybridization platform. Our easy to read report available electronically, based upon the presence (Detected) or absence (Not Detected) of the viruses, bacteria, or parasites within the panel will allow our clients to rapidly choose a treatment option.

Test information

Description Gastrointestinal Panel
Method Integrated multiplex PCR and bead array technology
CPT Code 87507
ICD10 Codes A09: Infectious gastroenteritis and colitis, unspecified
R11.0: Nausea
R11.10: Vomiting, unspecified
R19.7: Diarrhea, unspecified
R50.9: Fever, unspecified
Specimen Requirements Stool in Cary Blair
Turnaround Time 24 Hrs
Shipping Pickup/Fedex Service Available Monday – Friday
Testing Performed Monday-Saturday